CONGESTIVE HEART FAILURE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Congestive Heart Failure Market Size and Forecast – 2025 to 2032

The Global Congestive Heart Failure Market is estimated to be valued at USD 24.95 Bn in 2025 and is expected to reach USD 40.85 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032. The market growth is driven by factors such as the increasing prevalence of cardiovascular diseases, the rising geriatric population, and the growing adoption of advanced treatment options.

Key Takeaways of the Global Congestive Heart Failure Market:

• By type, the systolic heart failure segment is expected to account for the largest market share at 35.6% in 2025.
• By diagnosis, the echocardiography segment is expected to hold the dominant share at 32.4% in 2025.
• By device type, the pacemakers segment is expected to lead the segment with a 25.4% market share in 2025.
• In 2025, North America is expected to lead the market (41.3%) in 2025 while Asia Pacific is expected to grow the fastest (35.2%) in 2025 driven by aging population and rising heart disease cases

Market Overview:

The trend of the congestive heart failure market is characterized by the development of innovative therapies, such as gene therapy and stem cell therapy, which are expected to revolutionize the treatment landscape. Additionally, the increasing focus on personalized medicine and the growing demand for remote monitoring devices are expected to shape the market's future. Furthermore, the rising awareness about early diagnosis and treatment of congestive heart failure is anticipated to drive the market growth in the coming years.

Currents Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Analysis

To learn more about this report, Request sample copy

Congestive Heart Failure Market Insights, By Type – Systolic Heart Failure: Most Prevalent and Clinically Significant Segment

In terms of type, the systolic heart failure segment is expected to contribute the highest share of the market with 35.6% in 2025 owing to its high prevalence and the severity of its symptoms. Systolic heart failure occurs when the heart's left ventricle loses its ability to contract normally, resulting in reduced ejection fraction and inadequate blood supply to the body. This type of heart failure is often associated with coronary artery disease, hypertension, and valvular heart disease.

The high prevalence of risk factors such as obesity, diabetes, and unhealthy lifestyles contributes to the increasing incidence of systolic heart failure. Moreover, the aging population is more susceptible to developing this condition, further driving the market growth. Systolic heart failure often presents with severe symptoms such as shortness of breath, fatigue, and edema, leading to frequent hospitalizations and increased healthcare costs. The dominance of systolic heart failure in the market is also attributed to the focus on developing targeted therapies and devices for its management.

Congestive Heart Failure Market Insights, By Diagnosis – Echocardiography: Most Widely Used and Cost-Effective Diagnostic Tool

In terms of diagnosis, the echocardiography segment is expected to contribute the highest share of the market with 32.4% in 2025 due to its non-invasive nature, wide availability, and cost-effectiveness. Echocardiography is a crucial tool for evaluating heart structure and function in patients with suspected or diagnosed congestive heart failure. It provides valuable information on left ventricular ejection fraction, wall motion abnormalities, and valvular function, aiding in the accurate diagnosis and staging of the disease.

The increasing prevalence of congestive heart failure and the growing awareness about early diagnosis drive the adoption of echocardiography. Moreover, technological advancements such as 3D echocardiography and strain imaging have enhanced the diagnostic accuracy and prognostic value of this modality. These advancements enable better visualization of cardiac structures and quantification of myocardial deformation, facilitating personalized treatment decisions.

Congestive Heart Failure Market Insights, By Device Type – Pacemakers: Dominant Segment Due to Their Critical Role in Rhythm Management

In terms of device type, the pacemakers segment is expected to contribute the highest share of the market with 25.4% in 2025 due to their essential role in managing conduction abnormalities and improving cardiac function in patients with congestive heart failure. Pacemakers are implantable devices that regulate the heart's rhythm by delivering electrical impulses to the heart muscle, ensuring adequate heart rate and synchronization of cardiac chambers.

The increasing prevalence of congestive heart failure and the associated conduction disorders drive the demand for pacemakers. Patients with congestive heart failure often develop bradycardia, atrioventricular block, or bundle branch block, which can be effectively treated with pacemaker therapy. Moreover, the growing geriatric population, who are more prone to developing conduction abnormalities, further fuels the adoption of pacemakers.

Regional Insights

To learn more about this report, Request sample copy

North America Congestive Heart Failure Market Analysis and Trends

North America’s dominance in the global congestive heart failure market with an estimated share of 41.3% in 2025 can be attributed to several factors. The region boasts a well-established healthcare infrastructure, with advanced medical facilities and a strong emphasis on research and development. The presence of major pharmaceutical and biotechnology companies, such as Pfizer, Merck, and Johnson & Johnson, has significantly contributed to the growth of the market.

These companies have been actively involved in developing innovative treatments and therapies for congestive heart failure. Moreover, favorable government policies and initiatives aimed at improving patient care and access to healthcare services have further propelled the market growth in North America. The region's high healthcare expenditure and increasing prevalence of cardiovascular diseases have also played a crucial role in its dominant position.

Asia Pacific Congestive Heart Failure Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth in the global congestive heart failure market with 35.2% in 2025. This growth can be attributed to several factors, including the rising prevalence of cardiovascular diseases, increasing healthcare expenditure, and growing awareness about early diagnosis and treatment. Countries like China and India have emerged as significant players in the Asia Pacific congestive heart failure market, driven by their large patient populations and growing middle class with increased disposable income.

Additionally, government initiatives to improve healthcare access and affordability have further fueled the market growth in the region. For instance, in August 2023, Lupin Digital Health (LDH), a leading cardiac digital therapeutics company in India, announced the launch of its latest innovation — the Lyfe Digital Heart Failure Clinic. This virtual clinic is designed to support cardiologists and caregivers in managing heart failure patients remotely, offering effective care from the comfort of patients' homes.

Global Congestive Heart Failure Market Outlook for Key Countries:

U.S. Congestive Heart Failure Market Trends

The U.S. congestive heart failure market is characterized by a strong emphasis on research and development, leading to the introduction of advanced treatment options. Major players such as Novartis, AstraZeneca, and Bristol-Myers Squibb have a significant presence in the country, actively engaging in product development and strategic collaborations.

The country's aging population and increasing prevalence of risk factors, such as obesity and diabetes, have also contributed to the demand for congestive heart failure treatments. For instance, in January 2025, Bayer asked the U.S. FDA to approve a new use for its drug KERENDIA (finerenone) to treat people with heart failure in the U.S. who have a left ventricular ejection fraction (LVEF) of 40% or higher. This request is based on strong results from a recent clinical study (FINEARTS-HF), which showed the drug helps these patients.

China Congestive Heart Failure Market Trends

China congestive heart failure market is driven by the country's large patient population and increasing healthcare expenditure. The government's efforts to reform the healthcare system and expand insurance coverage have improved access to medical services.

For instance, on August 18, 2023, AstraZeneca announced that its drug Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death and hospitalization in adults with symptomatic chronic heart failure, regardless of ejection fraction. Previously approved for patients with reduced ejection fraction (HFrEF), this makes Forxiga the first heart failure therapy in China with proven mortality benefit across all ejection fraction types.

Germany Congestive Heart Failure Market Trends

Germany continues to lead the Europe market for congestive heart failure, backed by its strong healthcare system and focus on research and innovation. The country is home to renowned pharmaceutical companies such as Bayer and Boehringer Ingelheim, which have made significant contributions to the development of congestive heart failure therapies.

For instance, in November 2024, a research team from the University Medical Centre Göttingen (UMG) and University Medical Centre Schleswig-Holstein (UKSH) won the German University Medicine Award for developing a groundbreaking ‘heart patch’ therapy. This stem cell-based patch helps repair and strengthen damaged heart muscle and was tested in humans during the BioVAT-DZHK20 clinical trial, supported by the German Centre for Cardiovascular Research (DZHK).

Japan Congestive Heart Failure Market Trends

Japan congestive heart failure market is characterized by an aging population and a high prevalence of cardiovascular diseases. The country's well-developed healthcare system and strong emphasis on research and development have supported the growth of the market. Japanese pharmaceutical companies, such as Takeda and Daiichi Sankyo, have been actively involved in developing and commercializing congestive heart failure treatments.

For instance, in February 2025, Bayer, a pharmaceutical company, submitted a marketing application to Japan’s Ministry of Health, Labour and Welfare (MHLW) seeking approval of finerenone for adults with chronic heart failure and LVEF ≥40% (HFmrEF and HFpEF). Backed by positive results from the Phase III FINEARTS-HF study, this marks the first drug targeting the mineralocorticoid receptor pathway to show cardiovascular benefits in this patient group.

End User Feedback and Unmet Needs – Global Congestive Heart Failure Market

End users such as hospitals and home healthcare providers have expressed strong satisfaction with non-invasive diagnostic tools and wearable cardiac monitors. AI-based echocardiography has been particularly praised for improving diagnostic accuracy and reducing reliance on specialist availability. Home care teams also value remote monitoring systems for enabling real-time patient tracking and reducing hospital readmissions, especially in aging populations and rural settings.

However, concerns remain around affordability and device interoperability. Users in emerging markets report limited access to advanced therapies like CRT and implantable defibrillators due to high costs and poor insurance coverage. Additionally, fragmented health IT systems hinder data integration across platforms. Addressing these needs—through affordable, interoperable, and customizable solutions—could unlock growth in underserved regions and enhance long-term user engagement.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Request sample copy

Key Developments:

• In February 2025, HCF, Australia’s largest not-for-profit health insurers, partnered with Ramsay Connect, a global private healthcare provider, which now offers a Virtual Heart Failure Service to over 2 million members, enabling remote monitoring of vitals like blood pressure, pulse, oxygen levels, and weight. Ramsay nurses oversee patient data, and virtual consultations provide lifestyle management support.
• In January 2025, the American Heart Association, a U.S.-based non-profit organization, launched a USD 3 million initiative, backed by Abbott, a global healthcare company, to enhance heart failure (HF) care by promoting advanced treatment pathways and improving clinician education. The program targets gaps in access to specialty care, especially for underserved populations, aiming to improve outcomes for the growing HF population in the U.S.
• In August 2024, Eli Lilly’s, a multinational pharmaceutical company, tirzepatide showed positive phase 3 results in the SUMMIT trial for patients with heart failure with preserved ejection fraction (HFpEF) and obesity. It significantly improved heart failure outcomes and KCCQ-CSS scores versus placebo. Secondary endpoints met include improved exercise capacity (6MWD), reduced hsCRP, and up to 15.7% body weight reduction at 52 weeks.
• In September 2024, KERENDIA (finerenone) achieved a 16% reduction in the composite of cardiovascular death and total heart failure events in patients with HF and Left Ventricular Ejection Fraction, LVEF ≥40% in the Phase III FINEARTS-HF trial, as presented at ESC 2024 and published in NEJM. It is the first non-steroidal MRA to meet a primary CV endpoint in this patient group.

Top Strategies Followed by Global Congestive Heart Failure Market Players

• Established players in the global congestive heart failure market are focusing on extensive research and development to innovate high-performance products. These companies invest heavily in R&D to develop advanced treatments, medical devices, and diagnostic tools to improve patient outcomes.
  • For instance, In November 2024, Cardiovascular Disease National Collaborative Enterprise, (CADENCE) and Medera Inc., a U.S.-based biotech firm through its subsidiary, Sardocor, have launched Asia’s first multi-center gene therapy trial for heart failure, with Singapore as the only site outside the U.S.

• Mid-level players in the market are focusing on delivering cost-effective solutions to target price-sensitive consumers. These companies aim to provide quality products at affordable prices, making treatment accessible to a wider population. They also engage in collaborations with technology providers and production partners to boost their capabilities and market presence.
  • For instance, in January 2025, Alleviant Medical, Inc., a U.S.-based private medical device company developing a no-implant atrial shunt for heart failure, received the U.S. FDA IDE approval to launch a pivotal trial for HFrEF patients.

• Small-scale players in the global congestive heart failure market often specialize in niche areas, offering unique features or innovative products. These companies target specific market segments with differentiated offerings, such as personalized treatment plans or advanced diagnostic tools.
  • For instance, in March 2025, Morepen Laboratories, a pharmaceutical company, announced the launch of Empamore, a cost-effective treatment for type 2 diabetes, heart failure, and chronic kidney disease. The drug, based on empagliflozin, is available in 10mg and 25mg doses, and combination forms with metformin.

Market Report Scope

Congestive Heart Failure Market Dynamics

To learn more about this report, Request sample copy

Congestive Heart Failure Market Driver - Increasing Prevalence of Cardiovascular Diseases

The rising prevalence of cardiovascular diseases worldwide is a significant driver for the growth of the global congestive heart failure market. Cardiovascular diseases, such as coronary artery disease, hypertension, and valvular heart disease, are major risk factors for the development of congestive heart failure. As the global population continues to age and adopt unhealthy lifestyles characterized by poor dietary habits, physical inactivity, and increased stress levels, the incidence of cardiovascular diseases is expected to rise. Moreover, the growing prevalence of obesity, diabetes, and metabolic syndrome further contributes to the increased risk of developing cardiovascular diseases and, subsequently, congestive heart failure.

For instance, according to American Heart Association, Inc., in January 2025, heart disease and stroke statistics update, heart disease remains the top cause of death in the U.S., surpassing cancer and accidental deaths combined. Despite medical advances extending patient lives, major risk factors like high blood pressure and obesity continue to rise sharply, fueling the persistent threat of cardiovascular diseases. The findings, published in Circulation, emphasize the urgent need for public health interventions to address these escalating health risks.

Congestive Heart Failure Market Opportunity - Development of Novel Therapies

The development of novel therapies presents a significant opportunity for the global congestive heart failure market. As the understanding of the underlying mechanisms and pathophysiology of congestive heart failure continues to expand, researchers and pharmaceutical companies are actively working on developing innovative treatment approaches. These novel therapies aim to address the root causes of the disease, improve cardiac function, and enhance patient outcomes.

One promising area of research is gene therapy, which involves the introduction of therapeutic genes into the heart to promote the regeneration of damaged cardiac tissue. Another avenue of exploration is the use of stem cell therapy, where stem cells are delivered to the heart to stimulate the formation of new, healthy cardiac cells.

For example, In September 2024, Duke-NUS Medical School researchers, in collaboration with international partners, have identified a promising new treatment for heart failure with preserved ejection fraction (HFpEF)—a condition that affects nearly half of the 64 million people living with heart failure globally.

Analyst Opinion (Expert Opinion)

• The global congestive heart failure market is experiencing steady growth driven by rising prevalence of cardiovascular diseases, increased geriatric population, and continuous advancements in diagnostic and therapeutic technologies such as implantable cardiac devices and gene therapy. Supportive regulatory frameworks and initiatives by organizations like the U.S. FDA and EMA to fast-track innovative treatment approvals have further accelerated market expansion. However, the market continues to face challenges such as high treatment costs, limited access to advanced care in low-income regions, and a shortage of cardiologists in emerging economies. Nevertheless, emerging opportunities lie in the integration of digital health solutions, AI-powered diagnostic tools, and gene therapy innovations tailored for personalized care.
• Key developments shaping the congestive heart failure market include the launch of Asia’s first multi-center gene therapy trial by Medera and CADENCE in 2024, targeting heart failure patients in Singapore and the U.S. This reflects growing interest in regenerative medicine. Additionally, global conferences like the European Society of Cardiology Congress, Heart Failure Society of America (HFSA) Scientific Meeting, and World Congress on Cardiology and Cardiovascular Health have played a pivotal role in disseminating research, fostering global collaborations, and shaping policy discourse around congestive heart failure management. These events continue to drive knowledge exchange and innovation within the sector.

Market Segmentation

•  Type Insights (Revenue, USD Bn, 2020 - 2032)
• • Systolic Heart Failure
  • Diastolic Heart Failure
  • Acute Heart Failure
  • Chronic Heart Failure
•  Diagnosis Insights (Revenue, USD Bn, 2020 - 2032)
• • Echocardiography
  • Chest X-Ray
  • Blood Tests (BNP, NT-proBNP)
  • Cardiac Catheterization
  • Magnetic Resonance Imaging
  • Holter Monitoring
  • Nuclear Imaging
•  Device Type Insights (Revenue, USD Bn, 2020 - 2032)
• • Pacemakers
  • Implantable Cardioverter-Defibrillators (ICDs)
  • Cardiac Resynchronization Therapy (CRT) Devices
  • Ventricular Assist Devices (VADs)
  • Remote Monitoring Devices
  • Others
•  Gender Insights (Revenue, USD Bn, 2020 - 2032)
• • Male
  • Female
•  Age Group Insights (Revenue, USD Bn, 2020 - 2032)
• • Adult
  • Pediatrics
  • Geriatric
•  End User Insights (Revenue, USD Bn, 2020 - 2032)
• • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Home Healthcare
  • Academic and Research Institutes
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • Novartis
  • Boehringer Ingelheim
  • AstraZeneca
  • Johnson & Johnson
  • Abbott
  • Medtronic
  • Boston Scientific
  • Pfizer
  • Merck & Co
  • Bristol Myers Squibb
  • LivaNova
  • Biotronik
  • V-Wave
  • Impulse Dynamics
  • CVRx

Sources

Primary Research Interviews:

• Cardiologists and Cardiovascular Surgeons: Insights on current treatment approaches, patient demographics, and unmet needs.
• Clinical Researchers and Trial Coordinators: Feedback on emerging therapies, gene therapy trials, and regulatory hurdles.
• Hospital Procurement Managers: Understanding trends in demand for heart failure therapeutics and devices.
• Patients and Advocacy Groups: Firsthand information on therapy effectiveness, cost burden, and accessibility challenges.

Databases:

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• European Medicines Agency (EMA)
• U.S. Food and Drug Administration (FDA)
• Global Burden of Disease Study (GBD – IHME)

Magazines:

• Cardiovascular Business
• PharmaVoice
• MedTech Dive
• Medical Device and Diagnostic Industry (MD+DI)
• BioPharma Dive

Journals:

• Journal of the American College of Cardiology (JACC)
• European Heart Journal
• Circulation: Heart Failure
• The Lancet: Cardiovascular Medicine
• Heart Failure Reviews
• American Journal of Cardiology

Newspapers:

• The Wall Street Journal – Business impacts of congestive heart failure drug/device launches.
• The New York Times – Public health reporting on heart disease trends.
• The Guardian – Global healthcare policy coverage, especially for EU and developing markets.
• Financial Times – Analysis of healthcare sector investments and innovations.

Associations:

• American Heart Association (AHA)
• Heart Failure Society of America (HFSA)
• European Society of Cardiology (ESC)
• Global Heart Hub
• Indian Heart Association (IHA)

Public Domain Sources:

• U.S. Food and Drug Administration (FDA) – congestive heart failure drug and device approval database.
• ClinicalTrials.gov – Global congestive heart failure trial data and pipeline monitoring.
• World Economic Forum (WEF) – Insights on aging populations and non-communicable disease preparedness.
• American College of Cardiology (ACC) Annual Meeting
• ESC Congress
• HFSA Annual Scientific Meeting

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years